Learn how a tesa/ipa blend protocol is typically structured, including dosing, timing, cycle length, side effects, and why no standard protocol exists.
There is no single FDA-approved tesa/ipa blend protocol. In practice, a tesamorelin/ipamorelin blend protocol usually means one subcutaneous injection per day, often at bedtime on an empty stomach, continued for 8 to 12 weeks. Doses depend on the ratio in the vial and should be set with a healthcare professional, because tesamorelin and ipamorelin have different approval statuses and side effect profiles.
What Is a Tesa/IPA Blend?
A tesa/ipa blend combines tesamorelin, a growth hormone–releasing hormone (GHRH) analog, with ipamorelin, a selective growth hormone secretagogue. The idea is to pair two compounds that stimulate growth hormone release through different pathways.
Tesamorelin is FDA-approved under the brand name Egrifta for HIV-associated lipodystrophy. Ipamorelin is not FDA-approved for human use in the United States. No regulatory agency has approved the combination as a single product.
Tesamorelin mimics GHRH, signaling the pituitary to release growth hormone. Ipamorelin mimics ghrelin, triggering growth hormone release through a different receptor. Some users believe the combination produces a stronger pulse, but that idea comes from animal and early-stage research, not large human trials.
Many researchers also look into tesa ipa cjc blend options, which add CJC-1295 to the mix. That adds another variable and more uncertainty about dosing and safety.
How the Two Peptides Differ
| Feature | Tesamorelin | Ipamorelin |
|---|---|---|
| FDA status | Approved for HIV lipodystrophy | Not approved for human use |
| Mechanism | GHRH analog | Ghrelin receptor agonist |
| Typical research dose | 1–2 mg daily | 100–300 mcg 1–3x daily |
| Common timing | Once daily, bedtime | Often bedtime or post-workout |
| Main monitored marker | IGF-1, blood glucose | IGF-1, hunger, joint comfort |
Typical Tesa/IPA Blend Protocol Variables
Because blends lock the ratio, you cannot adjust tesamorelin and ipamorelin independently in a single vial. A fixed blend prevents fine-tuning each peptide's dose, which is a key limitation.
Timing matters because growth hormone is naturally released in pulses, especially during deep sleep. Injecting at bedtime is intended to align with that rhythm. Eating close to injection may blunt the effect, which is why many protocols recommend waiting at least two hours after the last meal.
The table below summarizes variables people commonly discuss. It is not a prescription or a recommendation.
| Variable | Common research practice | Notes |
|---|---|---|
| Dose | 1 mg tesa + 100–300 mcg ipa | Depends on vial ratio; check label |
| Frequency | Once daily | Some split ipa into 2–3 doses, but blends make this hard |
| Timing | Before bed, 2+ hours after last meal | Empty stomach may improve absorption |
| Cycle length | 8–12 weeks | No standard cycle exists |
| Off period | 4 weeks or longer | Used to reassess labs and side effects |
| Monitoring | IGF-1, fasting glucose, A1C | Ordered by a clinician |
How to Reconstitute and Inject
Most research blends arrive as a lyophilized powder. Reconstitution involves adding bacteriostatic water or sterile water, swirling gently, and storing the vial in a refrigerator.
Example: a 10 mg vial (5 mg tesamorelin + 5 mg ipamorelin) reconstituted with 2 mL of water gives 5 mg/mL total peptide. A 0.2 mL draw contains 1 mg of total blend. Because the ratio is 1:1, that 1 mg contains 500 mcg tesamorelin and 500 mcg ipamorelin — not the 1 mg tesamorelin dose used in clinical trials.
That math matters. A 1:1 blend cannot deliver 1 mg tesamorelin without also delivering 1 mg ipamorelin, which is far above typical ipamorelin research doses. This is why many people prefer separate vials over a fixed blend.
Store reconstituted vials in the refrigerator, protect them from light, and avoid shaking, which can damage the peptide. Follow the specific storage instructions from the supplier and discard according to the label.
Side Effects and Safety
Tesamorelin can raise IGF-1 and blood glucose, and it may cause injection-site reactions, joint pain, swelling, and numbness or tingling. Ipamorelin may cause increased hunger, headaches, and fatigue in some users.
Neither peptide is risk-free, and combining them does not eliminate those risks. People with diabetes, active cancer, or pituitary disease should not use these compounds without specialist guidance.
Bloodwork before, during, and after a cycle is the only way to track IGF-1 and metabolic changes objectively. A healthcare professional should interpret those results.
For comparison, other research protocols have their own monitoring needs. An aod 9604 dosage protocol, for example, focuses on different metabolic markers, while a mots-c peptide dosage protocol targets different pathways entirely.
Injection-site reactions are the most common complaint. Rotating sites and using sterile technique can reduce irritation. Any sign of infection, severe swelling, or persistent numbness should prompt medical attention.
Who Should Avoid a Tesa/IPA Blend
These compounds are not appropriate for everyone, and some groups face higher risk.
- People with active or treated cancer, because growth hormone and IGF-1 can influence cell growth.
- People with uncontrolled diabetes or high fasting glucose, because tesamorelin can affect blood sugar.
- People with pituitary disorders or prior pituitary surgery.
- Pregnant or breastfeeding women.
- Anyone under 18, since safety data in minors are lacking.
Even if none of those apply, a clinician should review medications and health history before any peptide protocol begins.
Common Questions and Community Claims
Online forums are full of personal experiences, but anecdotes are not clinical evidence. If you read tesa/ipa blend reddit threads, treat them as informal reports rather than guidance.
Some vendors sell a tesamorelin aod9604 cjc1295 ipamorelin 12mg blend dosage product. Combining four peptides in one vial makes it impossible to know which compound is causing benefits or side effects.
Another frequent topic is cost and sourcing. Peptides sold online may be mislabeled or impure, and third-party testing is not guaranteed. That makes self-dosing even riskier.
The Bottom Line
A tesa/ipa blend protocol is not standardized, and no health agency has approved the combination. Typical research practice is once-daily subcutaneous use for 8–12 weeks with lab monitoring, but that reflects community habits, not proven clinical guidance.
If you are considering tesamorelin, ipamorelin, or any peptide blend, talk with a licensed healthcare professional first. They can review your history, order labs, and help you weigh the real risks against unproven benefits.
RELATED PEPTIDE TOPICTesamorelin peptide researchFrequently Asked Questions
What is the typical tesa/ipa blend dose?
There is no standard dose. Community protocols often mention 1 mg tesamorelin and 100–300 mcg ipamorelin daily, but a fixed blend locks the ratio, so the actual amount depends on the vial. A clinician should determine dosing based on your health history and labs.
How long should a tesa/ipa blend protocol last?
Many people run 8 to 12 weeks followed by 4 weeks off, but no clinical guideline supports a specific cycle length. Bloodwork, side effects, and IGF-1 levels should guide any decision to continue or stop.
Is a tesa/ipa blend FDA-approved?
No. Tesamorelin is FDA-approved as Egrifta for HIV-associated lipodystrophy, but ipamorelin is not FDA-approved for human use, and the combination is not approved. Using them together is an unregulated practice with unknown risks.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.